Regenerx Biopharmaceuticals Inc Stock: price and insider trades · United States

RegeneRx Biopharmaceuticals, Inc. (ticker RGRX) is a U.S.-based biopharmaceutical company headquartered in Rockville, Maryland, United States. In market context, it is best understood as a small-cap biotech with a public listing on the OTC market rather than NYSE/NASDAQ, despite the user’s requested exchange framing. RegeneRx operates as a virtual biopharmaceutical company, meaning it maintains a relatively lean internal infrastructure and relies heavily on partnerships, licensing arrangements, and external clinical development support. Its scientific focus is centered on tissue protection, repair, and regeneration, built around its proprietary peptide platform based on thymosin beta 4 (Tβ4) and related analogues, derivatives, and fragments.

The company’s lead asset is RGN-259, an ophthalmic drug candidate being developed primarily for neurotrophic keratitis (NK) and dry eye disease. RegeneRx states that RGN-259 is in Phase 3 clinical trials in the U.S. and EU for NK, an orphan eye disease with limited treatment options. That positioning matters: rather than trying to compete head-on in crowded large-market categories, RegeneRx is targeting a niche indication where clinical differentiation and regulatory success could be especially valuable. The company’s broader historical pipeline has also included candidates for dermal, cardiac, and central/peripheral nervous system applications, but the strategic emphasis has increasingly shifted toward ophthalmology.